Kura Oncology Hosts Virtual Investor Event on Ziftomenib Triplet Data in Acute Myeloid Leukemia

Kura Oncology Inc. will host a virtual analyst and investor event on December 8, 2025, at 12:30 PM ET to discuss data presented at the ASH 2025 meeting on the triplet combination of ziftomenib (KOMZIFTI®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The event will feature members of the management team and lead investigators, with a live webcast and replay available on the company’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595883-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)